Christoph Hiemke

Christoph Hiemke's AcademicInfluence.com Rankings

Christoph Hiemke

Computer Science

#6985

World Rank

#7355

Historical Rank

Machine Learning

#2436

World Rank

#2467

Historical Rank

Artificial Intelligence

#2719

World Rank

#2761

Historical Rank

Database

#4048

World Rank

#4209

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Christoph Hiemke Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christoph Hiemke's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacokinetics of selective serotonin reuptake inhibitors. (2000) (767)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2017) (714)
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. (2004) (619)
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. (2014) (555)
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 (2011) (506)
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. (2004) (455)
Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment (2006) (394)
Chronic Social Stress Inhibits Cell Proliferation in the Adult Medial Prefrontal Cortex: Hemispheric Asymmetry and Reversal by Fluoxetine Treatment (2007) (330)
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine (2006) (231)
Psychosocial stress in tree shrews: Clomipramine counteracts behavioral and endocrine changes (1996) (178)
Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting (2004) (168)
Strain Differences in Open-Field and Elevated Plus-Maze Behavior of Rats Without and With Pretest Handling (1998) (163)
Elevated levels of clozapine in serum after addition of fluvoxamine. (1994) (162)
Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. (1998) (152)
Identification of P‐glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates (2004) (134)
Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats (2006) (131)
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. (2008) (130)
Pregabalin abuse and dependence in Germany: results from a database query (2013) (113)
Therapeutic Monitoring of New Antipsychotic Drugs (2004) (110)
Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam (2008) (108)
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects (2008) (107)
Kavapyrone enriched extract fromPiper methysticum as modulator of the GABA binding site in different regions of rat brain (1994) (104)
Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats (2006) (100)
The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia (2006) (97)
Combination of open field and elevated plus-maze: A suitable test battery to assess strain as well as treatment differences in rat behavior (1998) (95)
Increased bioavailability of oral melatonin after fluvoxamine coadministration (2000) (93)
The Chronic Psychosocial Stress Paradigm in Male Tree Shrews: Evaluation of a Novel Animal Model for Depressive Disorders (2002) (93)
Effects of Pulsed High-Frequency Electromagnetic Fields on the Neuroendocrine System (1998) (90)
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin (2014) (88)
Chronic psychosocial stress and antidepressant treatment in tree shrews: time-dependent behavioral and endocrine effects (1999) (87)
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus (2012) (86)
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians* (2018) (85)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2018) (83)
Expression of alpha subunit genes of nicotinic acetylcholine receptors in human lymphocytes (1996) (81)
The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy (2000) (80)
Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. (2006) (78)
Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin (2001) (78)
Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine (2002) (76)
Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat (2007) (76)
Neuroendocrine response to antipsychotics: effects of drug type and gender (1999) (75)
The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study (2011) (73)
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine (2006) (73)
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics (2016) (69)
Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. (1999) (67)
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. (1996) (65)
Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. (2007) (64)
Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects (2002) (64)
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. (2001) (64)
Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression (2012) (64)
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. (2005) (64)
Distribution of clozapine and desmethylclozapine between blood and brain in rats (1999) (63)
Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. (1992) (62)
Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? (2003) (62)
Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels (2016) (60)
Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine (2014) (60)
Diazepam Has No Beneficial Effects on Stress-Induced Behavioural and Endocrine Changes in Male Tree Shrews (2000) (59)
Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations (2020) (59)
Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. (1994) (59)
Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy (2001) (58)
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone (2017) (58)
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2021) (58)
A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients (2019) (57)
Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. (1992) (56)
Characterization of Escherichia coli O157:H7 from Downer and Healthy Dairy Cattle in the Upper Midwest Region of the United States (2003) (55)
Clinical utility of drug measurement and pharmacokinetics – therapeutic drug monitoring in psychiatry (2008) (55)
Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. (1995) (54)
High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. (2004) (54)
Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. (2002) (54)
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants (2005) (53)
Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice (2008) (53)
Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism (2007) (53)
Appropriateness of Therapeutic Drug Monitoring for Antidepressants in Routine Psychiatric Inpatient Care (2006) (52)
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp) (2006) (52)
Therapeutic Monitoring of Psychotropic Drugs: An Outline of the AGNP-TDM Expert Group Consensus Guideline (2004) (52)
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? (2008) (51)
Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. (1987) (51)
Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. (2003) (49)
Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. (2003) (48)
Serum concentrations of paliperidone versus risperidone and clinical effects (2010) (48)
Effects of escitalopram on the regulation of brain‐derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress (2009) (48)
Desomorphine Goes “Crocodile” (2012) (45)
Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein (2010) (45)
Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. (2007) (44)
Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone: A Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride (D2/D3-Receptor Occupancy of Ziprasidone) (2008) (44)
Interaction of non-steroidal antiestrogens with dopamine receptor binding. (1984) (44)
Toxic clozapine serum levels during inflammatory reactions. (2009) (44)
Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. (1999) (44)
Over-expression of two different forms of the α-secretase ADAM10 affects learning and memory in mice (2006) (43)
CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. (1997) (43)
Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. (2004) (42)
Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging (2011) (42)
Evaluation of naltrexone for dissociative symptoms in borderline personality disorder (2012) (42)
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. (2020) (41)
Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. (1991) (41)
Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice (2010) (41)
Population pharmacokinetic analysis of mirtazapine (2004) (40)
Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. (2000) (39)
Nonlinear pharmacokinetics of fluvoxamine and gender differences. (1998) (39)
Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels (2002) (39)
Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study (2015) (39)
Therapeutic drug monitoring for antidepressant drug treatment. (2012) (38)
Aripiprazole in pregnancy and lactation: a case report. (2010) (38)
Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On‐Line High‐Performance Liquid Chromatography (1994) (38)
The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions (2012) (38)
Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience. (1999) (37)
Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment (2013) (37)
Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography and HPLC. (1994) (37)
Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. (2010) (36)
Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression (2011) (36)
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. (2004) (36)
Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. (1992) (35)
P.5.c.002 Non-fatal and fatal liver failure associated with valproic acid (2012) (35)
Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine (2000) (35)
Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production (1995) (34)
How Does the Benzamide Antipsychotic Amisulpride get into the Brain?—An In Vitro Approach Comparing Amisulpride with Clozapine (2003) (34)
Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein (2012) (34)
Hormonal Influences on Cardiovascular Norepinephrine Transporter Responses in Healthy Women (2008) (34)
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. (2005) (34)
Reduction of clozapine-induced hypersalivation by pirenzepine is safe. (2004) (33)
Sex differences in allelic frequencies of the 5‐HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study (2000) (33)
Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients (2001) (33)
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats (2002) (33)
Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H](−)-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus (1983) (33)
Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. (1994) (32)
Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. (1998) (32)
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone (2018) (32)
Chronic Lithium Salt Treatment Reduces CRE/CREB-Directed Gene Transcription and Reverses Its Upregulation by Chronic Psychosocial Stress in Transgenic Reporter Gene Mice (2008) (32)
Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial (2016) (32)
Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum (2004) (31)
Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder (2011) (31)
Stimulation of immediate early gene expression by desipramine in rat brain (1997) (31)
Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection (2005) (31)
Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. (2009) (31)
HPMA based amphiphilic copolymers mediate central nervous effects of domperidone. (2011) (31)
A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone (2018) (31)
Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching. (1996) (31)
Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis (2016) (31)
Large Variability of Aripiprazole and Dehydroaripiprazole Serum Concentrations in Adolescent Patients with Schizophrenia (2008) (31)
Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions (2013) (30)
Automated determination of clozapine and major metabolites in serum and urine. (1997) (30)
The N-Demethylation of the Doxepin Isomers Is Mainly Catalyzed by the Polymorphic CYP2C19 (2002) (29)
Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. (2006) (29)
Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI (2015) (29)
Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology. (2016) (29)
Paroxetine serum concentrations in depressed patients and response to treatment. (2005) (29)
Pharmacokinetic patterns of risperidone-associated adverse drug reactions (2016) (28)
Effects of antipsychotic treatment on cognition in healthy subjects (2013) (28)
Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial (2010) (28)
Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. (2013) (28)
Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions (2014) (28)
Fishing for a drug: solid-phase microextraction for the assay of clozapine in human plasma. (1999) (27)
Measurement of Duloxetine in Blood Using High-performance Liquid Chromatography with Spectrophotometric Detection and Column Switching (2007) (27)
Serum Concentrations of Hydroxybupropion for Dose Optimization of Depressed Patients Treated With Bupropion (2014) (27)
Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study (2009) (27)
Effects of ovariectomy and steroid replacement on GABAA receptor binding in female rat brain (1991) (27)
Rotarod Impairment: Catalepsy-Like Screening Test for Antipsychotic Side Effects (2009) (27)
Chronic Oral Haloperidol and Clozapine in Rats: A Behavioral Evaluation (1999) (27)
Therapeutic Drug Monitoring in Italian Psychiatry (2011) (26)
“Krokodil”—Revival of an Old Drug with New Problems (2012) (26)
Concentration–Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges (2019) (26)
Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. (1998) (26)
Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism (2005) (26)
A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice. (2010) (26)
Sub-acute effects of interferon-α 2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans (1992) (26)
Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion (1996) (25)
Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram (2013) (25)
Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model (2011) (25)
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. (2003) (25)
Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients (2005) (25)
Tiagabine, a γ-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze (2002) (25)
Free-choice ethanol consumption under the influence of GABAergic drugs in rats. (2002) (24)
The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy (2013) (24)
Side effects related to potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy (2015) (24)
Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. (1998) (24)
Interactions and monitoring of antipsychotic drugs. (2012) (23)
Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns (2017) (23)
Increase in serum clomipramine concentrations caused by valproate. (2000) (23)
Aripiprazole in human milk. (2007) (23)
The role of cytochrome P450 2D6 in the metabolism of moclobemide (1996) (23)
Serotonergic modulation of response inhibition and re‐engagement? Results of a study in healthy human volunteers (2010) (23)
In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes (2012) (23)
Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. (2011) (23)
Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers (2000) (23)
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment (2016) (22)
The “DGPPN-Cohort”: a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients (2013) (22)
Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. (2009) (22)
Psychiatric Disorder (2020) (22)
The Serotonin Transporter Promoter Polymorphism (5-HTTLPR) Affects the Relation between Antidepressant Serum Concentrations and Effectiveness in Major Depression (2011) (22)
Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder (2009) (22)
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia (2009) (22)
Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations (2018) (21)
Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT (1996) (21)
Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale (2011) (21)
Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus (2013) (21)
Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism (2017) (20)
Effects of oestradiol benzoate and progesterone on luteinizing hormone release and catecholamine turnover in the preoptic-hypothalamic brain area of ovariectomized rats. (1983) (20)
Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil (2015) (20)
Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. (2006) (20)
Prediction of Antidepressant Response to Venlafaxine by a Combination of Early Response Assessment and Therapeutic Drug Monitoring (2014) (20)
Elevated risperidone serum concentrations during acute inflammation, two cases (2015) (20)
The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey (2009) (19)
Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain (1996) (19)
Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. (2009) (19)
Day- and nighttime content of monoamines and their metabolites in the pineal gland of rat and hamster (1994) (19)
LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum (2008) (19)
Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. (1997) (18)
Region specific distribution of levomepromazine in the human brain (2006) (18)
French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs (2010) (18)
What the clinician still has to be reminded of. (2004) (18)
Sex differences in GABAA receptor binding in rat brain measured by an improved in vitro binding assay (2004) (18)
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? (2016) (18)
Low concentration of ziprasidone in human milk: a case report. (2009) (17)
Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. (2009) (17)
Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine (2018) (17)
hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study (2016) (17)
Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. (2010) (17)
The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology. (2005) (17)
Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression (2013) (17)
Evidence that 3α-hydroxy-5α-pregnan-20-one is a physiologically relevant modulator of gaba-ergic neurotransmission (1991) (17)
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. (2020) (17)
High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature. (2009) (17)
Therapeutisches Drug-Monitoring in der Psychiatrie (2013) (16)
Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism. (2018) (16)
Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. (2015) (16)
Quantification of D 2-Like Dopamine Receptors in the Human Brain with 18 F-Desmethoxyfallypride (2002) (16)
Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. (1998) (16)
Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection (2015) (16)
Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers (2002) (16)
Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites. (1998) (16)
Reduced clearance of venlafaxine in a combined treatment with quetiapine (2018) (16)
Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. (2007) (16)
Simultaneous Automated Determination of Catecholamines, Serotonin, and Their Metabolites in Brain Tissue by HPLC and Electrochemical Detection (1993) (15)
Analysis of Multiple Antidepressant and Antipsychotic Drugs Including Active Metabolites in Serum of Psychiatric Patients by LC with Column Switching and Spectrophotometric Detection (2009) (15)
[Paroxetine: pharmacokinetics and pharmacodynamics]. (1994) (15)
Prevalence and sort of pharmacokinetic drug–drug interactions in hospitalized psychiatric patients (2020) (15)
Inhibition of dextromethorphan metabolism by moclobemide (1998) (15)
„Therapeutic drug monitoring“ in Epileptologie und Psychiatrie (2008) (15)
Gas-liquid chromatoographic properties of catecholamines, phenylethylamines and indolalkylamines as their propionyl derivatives (1978) (15)
Actions of sex hormones on the brain (1992) (15)
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers (2011) (15)
Spatial Learning and Expression Patterns of PP1 mRNA in Mouse Hippocampus (2010) (15)
Molecular cloning of rat G-protein-coupled receptor kinase 6 (GRK6) from brain tissue, and its mRNA expression in different brain regions and peripheral tissues. (1997) (14)
Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex (1984) (14)
Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. (2013) (14)
Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial (1998) (14)
Drug‐Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms (2016) (14)
Day- and night-time contents of monoamines and their metabolites in the medial preoptic area of the rat hypothalamus (1999) (14)
Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation (2020) (14)
Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients (1999) (14)
Cytochrome P450‐mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy (2017) (14)
Automated Determination of Trimipramine and N-Desmethyl-Trimipramine in Human Plasma or Serum by HPLC With On-Line Solid Phase Extraction (1995) (14)
[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects (1997) (14)
Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey (2015) (14)
Genetic structure and admixture in sheep from terminal breeds in the United States (2020) (14)
Behavioral Effects of GABAA Receptor Stimulation and GABA-Transporter Inhibition (2000) (13)
“There is no dose–response relationship in psychopharmacotherapy” vs “pharmacotherapy in psychiatry is based on ligand–receptor interaction”: a unifying hypothesis and the need for plasma concentration based clinical trials (2011) (13)
Therapeutic drug monitoring of antidepressants--clinical aspects. (2007) (13)
Therapeutisches Drug-Monitoring in der Psychiatrie Konsensus-Leitlinie der AGNP (2005) (13)
Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans. (2007) (13)
Effects of short-term exposure to catecholestrogens on catecholamine turnover in the preoptic-hypothalamic brain of ovariectomized rats (1982) (13)
Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. (2018) (13)
Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients (1997) (13)
Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases (2014) (13)
Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. (1999) (13)
[Drug-drug-interactions in psychiatry]. (2013) (12)
Determination of naltrexone and 6β-naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection (2010) (12)
Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABAA-receptor (2001) (12)
Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. (2001) (12)
Potentially inappropriate medication in older psychiatric patients (2020) (12)
Behavioural Consequences of P‐Glycoprotein Deficiency in Mice, with Special Focus on Stress‐Related Mechanisms (2012) (12)
QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients (2018) (12)
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants (2021) (12)
Polypharmacy and the risk of drug–drug interactions and potentially inappropriate medications in hospital psychiatry (2021) (12)
The action of 5α-dihydrotestosterone and antiandrogens on the activities of 5α-reductase and 3α-hydroxysteroid dehydrogenase in the pituitary gland of gonadectomized rats (1982) (12)
Sex-specific effects of estradiol on hypothalamic noradrenaline turnover in gonadectomized rats (2004) (11)
Chronical haloperidol and clozapine treatment in rats: Differential RNA display analysis, behavioral studies and serum level determination (1998) (11)
Sex and body weight are major determinants of venlafaxine pharmacokinetics (2018) (11)
Tiagabine, a gamma-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze. (2002) (11)
Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid. (2016) (11)
Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. (2000) (11)
Time-dependent effects of oestradiol and progesterone on hypothalamic catecholamine turnover in ovariectomized rats. (1985) (11)
Improved model for the induction of proestrus-like gonadotropin surges in long-term ovariectomized rats. (1987) (10)
[Pharmacogenetics, therapeutic drug monitoring and non compliance]. (2010) (10)
Distribution pattern of mirtazapine and normirtazapine in blood and CSF (2015) (10)
Determination of benperidol and its reduced metabolite in human plasma by high-performance liquid chromatography and electrochemical detection. (1991) (10)
Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood (2015) (10)
Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies (2014) (10)
Abuse liability of flupirtine revisited: Implications of spontaneous reports of adverse drug reactions (2013) (10)
Radiosynthesis of (±)‐(2‐((4‐(2‐[18F]fluoro‐ethoxy)phenyl)bis(4‐methoxy‐phenyl)methoxy)ethylpiperidine‐3‐carboxylic acid: a potential GAT‐3 PET ligand to study GABAergic neuro‐transmission in vivo (2001) (10)
[Genetic tests for controlling treatment with antidepressants]. (2017) (9)
Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study (2014) (9)
Rating The Delirogenic Potential of Drugs for Prediction of Side Effects in Elderly Psychiatric Inpatients (2015) (9)
Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice (2010) (9)
Characterization of Escherichia coli O 157 : H 7 from Downer and Healthy Dairy Cattle in the Upper Midwest Region of the United States (2003) (9)
Formation and metabolism of catecholestrogens in depressed patients (1990) (9)
Cerebrospinal Fluid Tau Protein Levels and 18F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis of Alzheimer’s Disease (2010) (9)
SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information (2010) (9)
Do catecholestrogens interact with the in vitro binding of radioligands to catecholamine receptors? (1983) (9)
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy (2020) (9)
Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. (2015) (9)
Quantitation of GABA transporter 3 (GAT3) mRNA in rat brain by competitive RT-PCR. (1999) (9)
Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction. (2014) (9)
Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants (2016) (9)
Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews (2021) (8)
No effect of six weeks of treatment with escitalopram on mood in healthy volunteers — Irrespective of genotype for the promoter of the serotonin transporter (2008) (8)
Amphiphilic Copolymers Shuttle Drugs Across the Blood-Brain Barrier. (2016) (8)
New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies (2002) (8)
Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders (2021) (8)
Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis (2021) (8)
[Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP]. (2014) (8)
Therapeutic drug monitoring in psychiatry. (2011) (7)
Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters (2011) (7)
Rapid cloning of cDNA ends polymerase chain reaction of G-protein-coupled receptor kinase 6: an improved method to determine 5'- and 3'-cDNA ends. (1999) (7)
No influence of dialysis on mirtazapine - a case report. (2008) (7)
Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders (2005) (7)
Therapeutic drug monitoring-based clozapine dosing recommendations. (2007) (7)
Determination of Homovanillic Acid in Human Plasma Using HPLC with Electrochemical Detection and Automated Solid Phase Extraction (1993) (7)
Non‐adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission (2019) (7)
Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. (2019) (7)
Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application (1994) (7)
Retrospective Pilot Study for Analysis of Antidepressant Serum Concentrations of Citalopram and Venlafaxine during Inflammation (2015) (7)
Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study (2021) (7)
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus (2012) (7)
Production of the Neurosteroid 3alpha‐Hydroxy‐5alpha‐pregnan‐20‐one in Man (1991) (7)
Pharmacodynamic Drug–Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients (2021) (7)
Diurnal Variations of Plasma Interleukin‐6 in Man: Methodological Implications of Continuous Use of Indwelling Cannulae (1995) (6)
[Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group]. (2006) (6)
Pharmacokinetic correlates of venlafaxine: associated adverse reactions (2019) (6)
The Acid Sphingomyelinase Sequence Variant p.A487V Is Not Associated With Decreased Levels of Enzymatic Activity. (2012) (6)
Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database (2019) (6)
Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents. (2020) (6)
Quetiapine and Norquetiapine Serum Concentrations and Clinical Effects in Depressed Patients Under Augmentation Therapy With Quetiapine (2013) (6)
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics (2017) (6)
Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients (2021) (6)
Therapeutic Drug Monitoring of Zuclopenthixol in a Double-Blind Placebo-Controlled Discontinuation Study in Adults with Intellectual Disabilities and Aggressive Behaviour (2013) (6)
Dose-related concentrations of neuro-/psychoactive drugs expected in blood of children and adolescents. (2020) (6)
Non-competitive inhibition of clomipramineN-demethylation by fluvoxamine (2005) (6)
Central Nervous System Drugs (2012) (6)
Re-establishment of stimulatory estradiol effects on luteinizing hormone secretion in long term ovariectomized rats (1984) (5)
Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder (2020) (5)
Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004–2011 (2016) (5)
Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients. (2009) (5)
Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample (2020) (5)
Serum Concentrations of Quetiapine and Clinical Effects (2005) (5)
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial. (2019) (5)
Pharmacokinetic interactions between clozapine and sertraline in smokers and non‐smokers (2020) (5)
Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent. (1998) (5)
Antioestrogen inhibition of oestradiol-induced alterations in hypothalamic noradrenaline turnover. (1985) (5)
Flupentixol: relevance of stereoselective therapeutic drug monitoring (2012) (5)
Prevalence and type of potential pharmacokinetic drug- drug interactions in old aged psychiatric patients (2015) (5)
Preliminary assessment of the imaging capability of the YAP-(S)PET small animal scanner in neuroscience (2006) (5)
Clinical relevance of TDM of SSRIs. (2006) (5)
The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism (2019) (5)
Pharmacodynamic Effects of Aripiprazole and Ziprasidone with Respect to P-Glycoprotein Substrate Properties (2013) (5)
Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors (2022) (5)
P-Glycoprotein Influence on the Brain Uptake of a 5-HT2A Ligand: [18F]MH.MZ (2011) (4)
Therapeutic drug monitoring (TDM) of quetiapine (2004) (4)
Pregabalin abuse and dependence in Germany: results from a database query (2013) (4)
Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders (2020) (4)
Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. (2017) (4)
[Assessment of possible drug-drug interactions in psychopharmacotherapy after hospital discharge using an interactive database]. (2011) (4)
Adenylyl cyclase activity is increased in younger, but decreased in older, alcoholic patients after detoxification. (2000) (4)
Excretion of 2- and 3-monomethyl ethers of 2-hydroxyestrogens in healthy male volunteers. (1996) (3)
Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection (2021) (3)
Evidence that 3 alpha-hydroxy-5 alpha-pregnan-20-one is a physiologically relevant modulator of GABA-ergic neurotransmission. (1991) (3)
Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis (2022) (3)
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs (2004) (3)
[Recommendations for therapeutic monitoring of antidepressants]. (2013) (3)
OpenDrugWiki - Using a Semantic Wiki for Consolidating, Editing and Reviewing of Existing Heterogeneous Drug Data (2010) (3)
Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole. (2004) (3)
Pharmakokinetik, Interaktionspotential und TDM: Wichtig bei atypischen Antipsychotika (2002) (3)
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (3)
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis (2022) (3)
Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine (2020) (3)
Personality: Neurobehavioural Foundation and Pharmacological Protocols (2014) (3)
[New facts of long-term prophylaxis for bipolar affective disorder]. (2014) (3)
Why do antidepressant therapies have such a poor success rate? (2016) (2)
Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder (2022) (2)
The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients (1995) (2)
Drug Monitoring in Psychiatric Patients:Which Approach is Userul to ImprovePsychopharmacotherapy? (1992) (2)
Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate (2021) (2)
Therapeutic Drug Monitoring of Naltrexone and 6&bgr;-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges (2018) (2)
O-2-8 Inhibition of clomipramine metabolism by fluvoxamine (In vivo and In vitro data) (1996) (2)
Simultaneous Determination of Eight Antidepressant and Two Antipsychotic Drugs With Metabolites in Plasma of Psychiatric Patients Using High Performance Liquid Chromatography (HPLC) with Column Switching and Spectrophotometric Detection (2008) (2)
Pharmacological validation of a chronic social stress model in rats: effects of citalopram, reboxetine, haloperidol and diazepam (2007) (2)
Concentrations of different antidepressants in plasma and cerebrospinal fluid under naturalistic conditions (2014) (2)
Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants: Erratum. (2016) (2)
Duloxetine enters the brain – but why is it not found in the cerebrospinal fluid (2015) (2)
Citation of the AGNP consensus guidelines for therapeutic drug monitoring in psychiatry 2004 in the scientific literature 2004 to 2011 (2012) (2)
Detection of TOAD-64 in adult rat brain as revealed by two-dimensional protein gel electrophoresis followed by MALDI mass spectrometry Possible modulatory effect of chronic haloperidol treatment (2002) (2)
Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene (2010) (2)
First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol. (2017) (2)
[Psychopharmacotherapy in patients with cardiovascular diseases]. (2012) (2)
Citalopram abolishes depressive-like symptoms evoked by chronic social stress in rats (2005) (2)
Therapeutic drug-monitoring for opiate-dependent patients receiving buprenorphine for substitution (2013) (2)
[Individualized treatment with tricyclic antidepressives. The pharmacogenetics of depression]. (2008) (2)
Affective State (2020) (2)
Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database (2021) (2)
P.3.008 Pharmacokinetic differences for risperidone between genders (2017) (2)
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. (2001) (2)
Correction to: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations (2020) (1)
NEUROENDOCRINOLOGICAL AND EEG SLEEP EFFECTS OF ROXINDOLE, A DOPAMINE AUTORECEPTOR AGONIST, IN SCHIZOPHRENIC AND DEPRESSED PATIENTS (1992) (1)
Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery (2013) (1)
[Antipsychotics for treatment of neuropsychiatric disorders in dementia]. (2013) (1)
Pharmakotherapie im Alter (2014) (1)
Making the Case for ‘Power Abuse Disorder' as a Nosologic Entity (2017) (1)
[Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice]. (2021) (1)
P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range (2021) (1)
Presentation of the AGNP-TDM expert group consensus guideline on „Therapeutic Monitoring of Psychotropic Drugs“ (2004) (1)
Brotizolam (2018) (1)
Serum concentrations of Duloxetine and Clinical Effects (2007) (1)
Plasma concentrations of citalopram in inpatients with acute major depression are predictive for later non-response. Data from an observational study (2011) (1)
Medication adherence determined by therapeutic drug monitoring in psychiatric outpatients with co-morbid substance abuse disorders (2011) (1)
Pharmacokinetic and Behavioural Effects of Antidepressants Given Orally via Drinking Water in Rats (2005) (1)
Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid under naturalistic conditions (2013) (1)
Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions (2021) (1)
Effects of antipsychotic treatment on psychopathology and motor symptoms in healthy volunteers (2011) (1)
Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy (2022) (1)
Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance (2016) (1)
P-4-2 D2-receptor occupancy related to neuroleptical doses, side effects and prolactin levels: A study with IBZM-SPECT (1995) (1)
Influence of the body mass index on serum levels of venlafaxine and its active metabolite O-desmethylvenlafaxine. Analysis of a large therapeutic drug monitoring database (2013) (1)
P-1071 - the AGNP-TDM Expert Group Consensus Guidelines 2004 -therapeutic Drug Monitoring in Psychiatry: Analysis of 199 Citations (2004 – 2011) (2012) (1)
Endocrine regulation of opioid receptors in the female rat brain (1989) (1)
Additive effects of sex, age and smoking on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions (2011) (1)
Macromol. Rapid Commun. 9–10/2011 (2011) (1)
[Use of summaries of product characteristics (SmPC) among family doctors and pharmacists in the context of the aut-idem regulation: Results of an exploratory cross-sectional survey]. (2020) (1)
High venlafaxine serum levels after prior fluoxetine medication. (2012) (1)
[Therapeutic drug monitoring of antidepressives--therapeutic and health economics advantages]. (2003) (1)
The temporal and extrastriatal D2/D3 receptor binding profile of aripiprazole in patients with schizophrenia (2007) (1)
S-60-5 Combination of clozazpine and SSRIS in schizophrenic patients (1996) (1)
B77 CITALOPRAM COUNTERACTS DEPRESSIVE-LIKE SYMPTOMS EVOKED BY CHRONIC SOCIAL STRESS IN RATS (2005) (1)
Excitatory Amino Acids and Their Antagonists (2015) (1)
[Different number of contraindications between summaries of product characteristics (SmPC) of drugs with the same active ingredients - an analysis of data from SmPCs of neuropsychiatric drugs]. (2019) (1)
Storage and Transport Stability of New Antidepressant and Antipsychotic Drugs (2005) (1)
Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
Pet imaging of D2-like dopamine receptors in the human brain with [18F]desmethoxyfallypride (1999) (1)
SERUM CONCENTRATIONS OF CLOZAPINE, CLOMIPRAMINE AND THEIR METABOLITES CORRELATED TO THEIR CONCENTRATIONS IN BRAIN (1999) (1)
Individualisierte Therapie mit trizyklischen Antidepressiva. Pharmakogenetik der Depression (2008) (0)
P-4-4 Induction of c-fos gene expression by the sigma receptor ligand and potential neuroleptic drug EMD 57445 in rat brain (1995) (0)
W05-01 - Rationale and Design of an RCT Comparing “EMC-Strategy” with TAU in Patients with Major Depression - the EMC Trial (2010) (0)
The interactions between COVID-19 drugs and psychotropic agents (2021) (0)
P.0911 Drug monitoring of aripiprazole, dehydroaripiprazole and the active moiety: A systematic review on the therapeutic reference range (2021) (0)
ULTRASOUND FAT AND MUSCLE MEASUREMENTS OF LIVE LAMBS AS A PREDICTOR OF CARCASS FAT AND MUSCLE MEASUREMENTS AND CHANGES IN ULTRASOUND RIB EYE AREA AND FAT THICKNESS AS LAMBS GROW (2005) (0)
Effects of concomitant cytochrome P450 inhibitors on the metabolism of citalopram: Analysis of data from routine therapeutic drug monitoring (TDM) (2013) (0)
Effects of gonadal steroid hormones on GABA receptors in the central nervous system (1989) (0)
Psychopharmacotherapy during pregnancy: Therapeutic drug monitoring (tdm) in maternal blood, amniotic fluid and umbilical cord blood (2015) (0)
Review for "Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids" (2020) (0)
[Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (0)
The German Network on Depression: TDM of New and Old Antidepressant Drugs (2005) (0)
Patterns of clozapine pharmacokinetics in patient subgroups with different body mass index (2020) (0)
Systematic TDM of antidepressants in psychiatric inpatients under naturalistic conditions (2007) (0)
Factors Affecting the Pharmacokinetics of Escitalopram – Data from a Naturalistic Study (2007) (0)
High performance liquid chromatography with electrochemical detection for the determination of estrogen-induced alterations in the activities of hypothalamic monoaminergic neurons (1988) (0)
Disturbed Vision under Treatment with Venlafaxine or Quetiapine in Association with Plasma Concentrations of the Drugs (2008) (0)
CLOZAPINE‐INDUCED INFLAMMATORY SIGNS AND PLASMA LEVELS OF CLOZAPINE AND MAJOR METABOLITES IN SCHIZOPHRENIC PATIENTS (1992) (0)
Learning and memory in the Morris water maze were differentially affected by diazepam and tiagabine (2005) (0)
Penetration of the enantiomers of venlafaxine and its metabolites into the brain in mice lacking P-glycoprotein (mdr1ab) (2008) (0)
Evaluation of a risk-scale for anticholinergic side-effects in elderly psychiatric inpatients (2012) (0)
Therapeutic drug monitoring of naltrexone in alcohol dependent patients (2009) (0)
Text Analysis and Drug Analysis: Therapeutic Drug Monitoring in the Prescription Information (2008) (0)
Contents Vol. 61, 2010 (2010) (0)
56 INHIBITORY EFFECTS OF FLUVOXAMINE ON THE METABOLISM OF CLOMIPRAMINE IN HUMAN AND RAT LIVER MICROSOMES (1995) (0)
EPA-0703 – Performance of the Hamilton Depression Rating Subscales to Predict Antidepressant Treatment Response in the Early Course of Treatment (2014) (0)
The Practice of TDM in an Austrian University Hospital Setting: What the Clinician Still has to be Reminded of ... (2005) (0)
Determination of Citalopram and its Main Metabolite Desmethylcitalopram in Human Serum by Column-Switching High Performance-Liquid Chromatography (HPLC) and Spectrophotometric Detection (2005) (0)
Side effects related to potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy (2014) (0)
S.16.05 Pharmacokinetics to rediscover psychotropics; the case of risperidone (2017) (0)
51 CYP2D6 PHENOTYPING BY AN AUTOMATED DETERMINATION OF DEXTROMETHORPHAN AND ITS MAIN METABOLITES IN HUMAN PLASMA (1995) (0)
10 How valid are therapeutic reference ranges for psychotropic drugs? (2020) (0)
Cost-effectiveness potential of therapeutic drug monitoring for depressed inpatients treated with citalopram by shortening of hospitalization (2012) (0)
Pharmakotherapie der Depression (2014) (0)
P-7-11 Benzodiazeine receptor occupancy during lorazepam treatment in relation to plasma levels: A study with iomazenil-SPECT (1995) (0)
NEUROENDOCRINOLOGICAL AND EEG SLEEP EFFECTS OF FLUVOXAMINE IN PATIENTS WITH MAJOR DEPRESSION (1992) (0)
Pharmacodynamics and pharmacokinetics of risperidone and paliperidone with respect to P-glycoprotein expression (2007) (0)
Improved therapeutic drug monitoring by intensified cooperation between physician and pharmacist (2011) (0)
Therapeutic drug monitoring (TDM) in plasma and amniotic fluid in pregnancy (2012) (0)
Pharmakotherapie bei Alterspatienten (2017) (0)
TDM in Psychiatry. First Update of the AGNP Consensus Guidelines (2008) (0)
Mirtazapine Plasma Levels: Application of a Modified Target Concentration Intervention (TCI) (2005) (0)
Effects of GABA-transporter (GAT) inhibitors on activity and anxiety in rats (1997) (0)
Effect of Estradiol on Catecholamine Turnover and on the Activities of Catecholamine Degrading Enzymes in Brain Areas of Ovariectomized Rats (1981) (0)
Effect of triglyceride and total cholesterol levels on the pharmacokinetics of clozapine in clozapine medicated patients (2016) (0)
Characterization of a progestin-binding protein in the liver of female rats (1987) (0)
Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF α/IFN α therapy (1992) (0)
Therapeutic drug monitoring of ziprasidone (2004) (0)
Flupentixol: relevance of stereoselective therapeutic drug monitoring (2012) (0)
The action of 5 alpha-dihydrotestosterone and antiandrogens on the activities of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase in the pituitary gland of gonadectomized rats. (1982) (0)
XIV Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP (2020) (0)
DIURNAL VARIATIONS IN ANTIGEN‐STIMULATED PROLIFERATION OF HUMAN LYMPHOCYTES (1992) (0)
WITHDRAWN: Association analysis between the early change of serum brain-derived neurotrophic factor (sBDNF) and final change of depression severity during antidepressant treatment: A pilot study. (2010) (0)
Drug safety related to agents used for opioid maintenance therapy (2017) (0)
Impact of inflammation processes on blood serum levels of olanzapine, quetiapine and risperidone (2009) (0)
Evaluation of a risk-scale for drug-induced QT-prolongation in elderly psychiatric inpatients (2013) (0)
Evaluation of P-glycoprotein modulation of Fluorine-18-fallypride (2010) (0)
Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests (2007) (0)
Concentrations of different antidepressants in plasma and cerebrospinal fluid of patients treated under naturalistic conditions (2014) (0)
Alteration of risperidone elimination during acute inflammation, two cases (2014) (0)
Naturalistic treatment of positive symptoms in schizophrenia with amisulpride: Are there gender differences? (2004) (0)
Retrospective analysis of Therapeutic Drug Monitoring data from patients with a bipolar disorder who are treated with lamotrigine (2014) (0)
Risperidone-induced extrapyramidal side effects (2016) (0)
Therapeutic drug monitoring of clozapine in schizophrenic outpatients (2009) (0)
DOPAMINE RECEPTOR STIMULATED cAMP, INDIVIDUALLY DIFFERENT DOPAMINERGIC INDUCED MOTILITY AND DOPAMINE RECEPTOR GENES (2000) (0)
Pharmacokinetic considerations in coprescription of perazine in risperidone medicated patients (2016) (0)
Determination and Kinetics of CYP450 Isoenzyme Catalyzing Melatonin Biotransformation (2000) (0)
Predictive Validity (2022) (0)
Distribution pattern of mirtazapine and normirtazapine in blood and CSF (2014) (0)
Short communication A determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection (2003) (0)
Prevalence of Lower-Than-Expected Plasma Levels in Medicated Patients Presenting for Acute Psychiatric Inpatient Treatment (2008) (0)
Influence of P-glycoprotein (P-gp) induction on the pharmacokinetics of risperidone and paliperidone in mouse brain (2009) (0)
Activities of Daily Living (2021) (0)
Authors’ Reply to Suhas et al.: Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation” (2021) (0)
QTc interval alterations during antidepressant treatment with escitalopram and venlafaxine (2022) (0)
Reality and rational of drug combinations in psychopharmacotherapy (2008) (0)
110 AUTOMATED DETERMINATION OF CLOZAPINE, N-DESMETHYLCLOZAPINE AND CLOZAPINE N-OXIDE BY COLUMN SWITCHING AND ON-LINE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (1995) (0)
Lamotrigine in Bipolar Disorders – Is there an Effective Therapeutic Reference Concentration? (2008) (0)
Measuring psychopathology by HAMD and CGI ratings to guide antidepressant treatment under naturalistic conditions (2011) (0)
P-glycoprotein (P-gp) affects the pharmacodynamics and of the atypical antipsychotic amisulpride (2004) (0)
Does Addiction (Alcohol, Benzodiazepines) Diseases Affect the Pharmacokinetics of Escitalopram? – Data from a Naturalistic Study (2008) (0)
Subject Index Vol. 61, 2010 (2010) (0)
PSYCHOPATHOLOGICAL AND ENDOCRINE EFFECTS OF INTERFERON‐ALPHA‐2 (1992) (0)
[Standardized documentation procedure as a basis for improvement of process quality of treatment in psychiatric hospitals]. (2003) (0)
[Therapeutic drug monitoring of new antidepressives and antipsychotics]. (2003) (0)
Effects of age, gender, smoking and co-medication on the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in everyday clinical practice (2009) (0)
2 Drug interactions in patients undergoing opioid maintenance therapy (2020) (0)
Dihydrotestosterone and Estradiol Regulating the Activity of 3α-Hydroxysteroid Dehydrogenase in the Pituitary Gland of the Rat: Action of Antiestrogens (1981) (0)
PLASMA LEVELS OF NEUROLEPTIC DRUG AND PROLACTIN AFTER ACUTE DOSES OF BENPERIDOL (1992) (0)
Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels (2015) (0)
Therapeutic drug monitoring for patients with bipolar disorders. Useful or useless (2014) (0)
The Influence of Therapeutic Drug Monitoring (TDM) and Objective Symptom Rating for Prediction of Antipsychotic Response to Second-Generation Antipsychotic Drugs (2008) (0)
Automated Analysis of Antipsychotic Drugs Using Liquid Chromatography with Column Switching (2005) (0)
Is the estrogen-induced LH-surge in female rats triggered by noradrenalin or adrenalin? (1986) (0)
Pharmacotherapy of old aged patients (2014) (0)
Flurazepam (2020) (0)
Therapeutic Drug Monitoring in Psychiatry (2011) (0)
Therapeutic drug monitoring and objective symptom rating for optimization of antipsychotic drug therapy (2007) (0)
Aripiprazole use during pregnancy and lactation (2011) (0)
Interaction of antiestrogens with the in vitro binding of radioligands to catecholamine receptors (1984) (0)
Retinoid-based therapy of Alzheimer's disease A proof of mechanism study (2011) (0)
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2022) (0)
12 Therapeutic Drug Monitoring in the relapse prevention treatment of alcohol dependence (2020) (0)
SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents (2012) (0)
The influence of inflammatory reactions on the serum concentration of clozapine (2009) (0)
Characterization of Escherichia coli O 157 : H 7 from Downer and Healthy Dairy Cattle in the Upper Midwest Region of the United States C (2017) (0)
Multi-Drug-Resistance proteins affect antipsychotic treatment: in vivo effects of aripiprazole (2007) (0)
Antipsychotic Drug Levels in Psychiatric Primary Care Patients (2008) (0)
BIDIRECTIONAL DRUG INTERACTIONS BETWEEN FLUVOXAMINE AND TRICYCLIC ANTIDEPRESSANTS (1992) (0)
Forced swim-test-related antidepressant effects depend on P-glycoprotein expression in the Blood-Brain-Barrier (2009) (0)
P.2.b.009 Regulation of the astrocytic proteins NDRG2 and GFAP in the rat hippocampus by chronic social stress: no reversal by citalopram (2012) (0)
Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis (2022) (0)
P-515 - CGI Rating to Predict Antidepressant Treatment Under Naturalistic Conditions (2012) (0)
Influence of Age, Gender, Smoking Habits and Comedication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions (2008) (0)
The clinical relevance of the pharmacological interaction between clozapine and sertraline (2019) (0)
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients (2016) (0)
Automated Determinationof Fluvoxaminein Plasma by Column-Switching High-PerformanceLiquid Chromatography (1992) (0)
Therapeutic drug monitoring of bupropion for depression (2012) (0)
P2-453 TESTING THE THERAPEUTIC POTENTIAL OF DOXYCYCLINE IN A DROSOPHILA MELANOGASTER MODEL OFALZHEIMER’S DISEASE (2019) (0)
Potentially Inappropriate Medication in Patients Admitted with Diagnosis of Delirium Superimposed on Dementia (2018) (0)
[Important to atypical antipsychotics: pharmacokinetics, interaction potential and therapeutic drug monitoring]. (2002) (0)
Monitoring clomipramine and its hydroxylated metabolites in serum by fluorescence polarization immunoassay compared with HPLC (1995) (0)
P.559 How to find therapeutic reference ranges for psychotropic drugs: combining population-derived pharmacodynamic and pharmacokinetic principles with an evidence-based methodological approach (2019) (0)
Candidate genes for learning and memory: microarray analysis of mouse hippocampi during acquisition of the Morris water maze task (2005) (0)
PT705. Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery (2016) (0)
Therapeutic drug monitoring (TDM) and clinical outcomes in forensic patients under clozapine therapy compared to therapies with other antipsychotic drugs (2012) (0)
Therapeutic drug monitoring of aripiprazole (2005) (0)
Costs and effectiveness of therapeutic drug monitoring in psychiatry (2004) (0)
Therapeutic Drug Monitoring (TDM) of donepezil in patients with Alzheimers dementia (2013) (0)
How to find the therapeutic reference range for psychoactive drugs (2016) (0)
Pharmacokinetic and Pharmacodynamic Principles (2020) (0)
Use Of Therapeutic Drug Monitoring In Depressive Inpatients Under Naturalistic Conditions: 91 (2005) (0)
39-149 The effects of subchronic paroxetine administration on sleep EEG and night-time endocrinological profiles in healthy male volunteers (1997) (0)
Personalised medicine in psychiatry? Yes, but how? (2014) (0)
14-138 Effect of antidepressant medication on the cytochrome P450 2D6 (CYP2D6) phenotype (1997) (0)
SUBCELLULAR DISTRIBUTION AND GONADAL REGULATION OF 3α-HYDROXYSTEROID DEHYDROGENASE (3α-HSDH) IN RAT PITUITARY (1980) (0)
O-18 - TDM in Patients With Substance Related Disorders (2012) (0)
A new model for the induction of proestrus-like LH surges by estradiol in long-term ovariectomized rats (1985) (0)
Does Functional Imaging of the CNS Replace Assessment of Drug Concentrations in Serum (2008) (0)
How much citalopram is equivalent to 50 ng/ml sertraline? Standardization of serum concentrations of six different SSRIs by measuring serotonin transporter occupancy (2011) (0)
Consequences of P-gp deficiency for the phenotype of FVB/N (mdr1a/1b -/-) mice and resulting alterations in HPA-System activity (2009) (0)
P.3.c.023 Treatment of different target syndromes of schizophrenia with amisulpride: a therapeutic drug monitoring study (2007) (0)
Pharmacokinetic patterns of risperidone-associated adverse drug reactions (2016) (0)
PHARMACOKINETICS A ND D ISPOSITION (2004) (0)
Subprojekt 3.8. des Kompetenznetzes „Depression/Suizidalität" im Teilprojekt 3 „Qualitätsmanagement in der Depressionsbehandlung" (2003) (0)
APOMORPHINE-INDUCED BEHAVIORAL-PATTERNS ARE ASSOCIATED TO D2-DOPAMINE RECEPTOR GENE POLYMORPHISMS (2000) (0)
Schizophrenia patients who smoke have a faster finger tapping rate (2002) (0)
Therapeutic drug monitoring for improved psychopharmacotherapy in elderly patients (2014) (0)
Induction of p-gp affects pharmacodynamics of its substrates (2013) (0)
Concentrations of Venlafaxine, Mirtazapine and Citalopram in serum and cerebrospinal fluid – a naturalistic approach (2015) (0)
What is an animal model ? (2005) (0)
Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie (2019) (0)
Serotonin-selektive Antidepressiva(SSRI, DSA) (2002) (0)
Pharmacokinetic considerations of different dosing regimens in clozapine medicated patients (2016) (0)
22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment (2020) (0)
Nocturnal Hormone Profiles in Healthy Humans Under the Influence of Pulsed High-Frequency Electromagnetic Fields (2001) (0)
CME Courses (0)
Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy. (1992) (0)
Validation of four drug interaction programs for psychopharmacotherapy (2011) (0)
Information search and software use in TDM laboratories – a survey (2011) (0)
Melperone but not metoprolol is a clinically relevant inhibitor of CYP2D6 (2014) (0)
Methylphenidate challenge test in adults with attention deficit/hyperactivity disorder (ADHD): Clinical effects and their predictors (2020) (0)
Rapid and Reliable Genotyping Procedure for Detection of Alleles with Mutation, Deletion or/and Duplication of the CYP2D6-Gene (2005) (0)
Repetitive Behavior (2021) (0)
14-18 Benzodiazepine receptor occupancy during benzodiazepine treatment measured with 1231-lomazenil-SPECT: A survey of different studies (1997) (0)
Antiestrogen inhibition of estradiol-induced alterations in hypothalamic catecholamine turnover (1987) (0)
Age-dependency of psychotropic drug-induced anticholinergic adverse reactions: Analysis of reports to the pharmacovigilance system AGATE (2013) (0)
Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications (2020) (0)
Ines Gaertner in Memoriam (2005) (0)
TDM in psychiatric hospitals. Data from a German survey (2014) (0)
Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database (2019) (0)
IN VITRO METABOLISM OF THE TRICYCLIC ANTIDEPRESSANT DOXEPIN (1999) (0)
Therapeutic Drug Monitoring of Antidepressants and Length of Stay of Psychiatric Inpatients (2005) (0)
Therapeutic drug monitoring (TDM) of donepezil (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christoph Hiemke?

Christoph Hiemke is affiliated with the following schools:

University of Mainz
RWTH Aachen University
University of Bonn

Christoph Hiemke's Academic­Influence.com Rankings

Why Is Christoph Hiemke Influential?

Christoph Hiemke's Published Works

Published Works

What Schools Are Affiliated With Christoph Hiemke?

Christoph Hiemke's AcademicInfluence.com Rankings